RBC Capital analyst Arun Viswanathan raised the firm’s price target on Chemours (CC) to $26 from $21 and keeps an Outperform rating on the shares as part of a broader research note previewing Q1 results among Commodity Chemicals names. Recent conversations with investor relations teams have indicated that lower supply is driving price action across petchems, with the potential for significant price uplift in the first half of the year to drive stronger earnings than previously expected, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CC:
- Chemours price target raised to $29 from $23 at UBS
- Chemours price target raised to $27 from $21 at Truist
- Chemours price target raised to $25 from $21 at Mizuho
- Neutral Outlook on Chemours as Stable Thermal Performance Offsets Titanium Dioxide Uncertainty and Below‑Consensus 2026 EBITDA
- Chemours Completes Major 2034 Senior Notes Refinancing